Xian Zeng
Chief Executive Officer Byterna Therapeutics
Dr. Xian Zeng is the Co-Founder and Chief Executive Officer of Byterna Therapeutics, a biotechnology company dedicated to advancing next-generation circular mRNA-based immunotherapies. Dr. Zeng earned his PhD in AI-Pharmaceutical Science from the National University of Singapore. Prior to co-founding Byterna Therapeutics, he served at the Fudan University School of Pharmacy, where he led interdisciplinary research spanning pharmaceutical sciences, artificial intelligence, and mRNA drug discovery.
Seminars
Thursday 12th November 2026
Circular mRNA In Vivo CAR-T for Cancer & Autoimmune Diseases
9:00 am
- Sharing innovations in cmCAR and CellectLNP technology enable a differentiable and highly extensible in vivo cell engineering platform
- Revealing how BR101, a bi-specific in vivo CAR-T pipeline based on cmCAR and CellectLNP, exhibits robust and systemic B-cell depletion and immunereset in NHP
- Exploring how an open-label, single-arm clinical trial has been initiated to evaluate safety and efficacy of BR101 in cancer and autoimmune diseases
